Search
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market. … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer.
Picrotoxin
go.drugbank.com/drugs/DB00466ExperimentalAlthough it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalThe resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. … Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. … [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition.
Synonyms: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-Nτ-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamideSimeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnLike all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor. … This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs.
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalIt is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamideCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGuanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Cethromycin
go.drugbank.com/drugs/DB06419Investigational[L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA. … [A203369] Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment
alpha-Linolenic acid
go.drugbank.com/drugs/DB00132ApprovedInvestigationalNutraceuticalWithdrawnIt is a component of many common vegetable oils and is important to human nutrition.
Mixtures: UltimateCare ONE NFGadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigational[A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151] … [A263146] Since gadoxetate uptake is mediated by organic anion-transporting polypeptides (OATPs) and liver tumor cells lack OATPs, liver tumors show a lack of contrast of enhancement and therefore heightening